Patients with metastatic or unresectable (advanced) pheochromocytoma or paraganglioma (PPGL) have poor prognoses and few treatment options. This multicenter, phase 2 trial evaluated the efficacy and ...

Background and Aims: During the long-term treatment of patients with hereditary haemochromatosis (HH) the authors observed that proton pump inhibitors (PPI) reduced the requirement for maintenance ...

Parkinson’s disease is a neurodegenerative disorder that affects the nervous system. Studies show that some cases are caused by genetic mutations, but hereditary causes are rare. Hereditary ...

The approval of Andembry is for use in adult and pediatric patients aged 12 years and older and is self-administered with once-monthly dosing delivered in 15 seconds or less via an autoinjector ...

Contests Circulars FDA Approves Once-Monthly Andembry for Hereditary Angioedema Jun 20, 2025 Updated Jun 20, 2025 Comments ...

FDA Approves Once-Monthly Andembry for Hereditary Angioedema Jun 20, 2025 Updated Jun 20, 2025 ...

The FDA has delayed its decision to approve a new treatment for hereditary angioedema, citing a heavy workload and limited resources. The drug, sebetralstat, developed by Kalvista Pharmaceuticals ...

WATERTOWN, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling with clustering antibodies that address the underlying ...

The FDA on Tuesday signed off on CSL’s Factor XIIa blocker garadacimab to prevent attacks in patients with hereditary angioedema. The biologic will be marketed under the brand name Andembry.